For UK healthcare professionals only. This promotional virtual meeting has been funded and organised by Alnylam UK Limited.

Click on the link below to access the prescribing information for AMVUTTRA®▼(vutrisiran).
Adverse Event Reporting can be found at the bottom of the page.

AMVUTTRA® Prescribing Information (UK)

From Red Flags to Referral: Earlier ATTR-CM Diagnosis, Referral Optimisation and the Oxford Amyloidosis Service Example

Wednesday 9th September 2026, 12:30 - 13:15 BST | To be held virtually

For UK healthcare professionals only. This promotional virtual meeting has been funded and organised by Alnylam UK Limited.

Please note that some of the sessions will include data specific to products from Alnylam UK Limited.
‍
AMVUTTRA® is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients and cardiomyopathy (ATTR-CM).
‍
AMVUTTRA® is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

AMVUTTRA® is recommended by NICE as an option for the treatment of transthyretin amyloidosis in adults with cardiomyopathy (TA1115).

AMVUTTRA® is recommended by NICE as an option for the treatment of hATTR in adults with stages 1 or 2 PN (TA868).

From Red Flags to Referral: Earlier ATTR-CM Diagnosis, Referral Optimisation and the Oxford Amyloidosis Service Example‍

Wednesday 9th September 2026, 12:30 - 13:15 BST
‍

Speakers
‍Dr William Moody
Consultant Cardiologist, Midlands Amyloidosis Service (MAS), University Hospitals Birmingham NHS Foundation Trust
‍
Dr Nik Sabharwal
Consultant Cardiologist, Oxford University Hospitals NHS Foundation Trust

‍Agenda
12:30 - 12:35 Welcome and introduction - Dr William Moody
12:35 - 12:40 Early action with AMVUTTRA®: evolving practice in ATTR-CM - Dr William Moody
12:40 - 12:50 From red flags to referral: the Oxford Amyloidosis Service perspective - Dr Nik Sabharwal
12:50 - 13:00 Optimising referrals to the UK Amyloidosis Network - Dr William Moody
13:00 - 13:15 Q&A - Dr William Moody and Dr Nik Sabharwal

Register for this event below:

REGISTER

If you have already registered, please join below:

JOIN

Stay in touch with Alnylam

CLICK HERE TO STAY IN TOUCH WITH ALNYLAM

To report an adverse event in the UK:

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard/mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Alnylam Pharmaceuticals at 0800 141 2569 (+44 1628 878 592) or medinfo@alnylam.com

For UK healthcare professionals only.
This promotional virtual meeting has been funded and organised by Alnylam UK Limited.
© 2026 Alnylam Pharmaceuticals, Inc. All rights reserved.
AMV-UK-00673 | July 2026